RestorGenex Corporation — 2014 Form 10-K
Period and identity: This filing is RestorGenex Corporation’s annual report for the fiscal year ended December 31, 2014, not a filing identified as Cervomed Inc. The company had repositioned from entertainment and sports businesses to an early-stage biopharmaceutical developer. Amounts below are in U.S. dollars.
Business context and pipeline
RestorGenex focused on ophthalmology, oncology and dermatology. Its lead candidate, RES-529, had completed two Phase I studies for age-related macular degeneration (AMD) and remained preclinical for glioblastoma. RES-440, a topical anti-androgen candidate for acne, had completed proof-of-concept work in tissue and animal models. The company had no products approved for sale and generated no revenue in 2014 or 2013.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $14.61 million | $12.80 million |
| Research and development expense | $2.86 million | $0.34 million |
| Loss from continuing operations | $14.35 million | $2.97 million |
| Net loss attributable to RestorGenex | $14.35 million | $2.64 million |
| Cash used in operating activities | $9.03 million | $1.18 million |
| Cash and cash equivalents at year-end | $21.88 million | $0.25 million |
| Working capital at year-end | $21.83 million | $(5.88) million |
Margins are not meaningful because there was no revenue. The 2014 loss included a $6.67 million intangible-asset impairment and $2.31 million of losses on settling notes payable. In 2013, reported results benefited from $10.62 million of gains related to derivative liabilities; the comparison is also affected by discontinued operations and acquisitions. The accumulated deficit was $75.29 million at year-end.
Financing activities provided $30.71 million of cash in 2014, principally from a private placement that raised approximately $35.6 million gross and $31.9 million net. The placement issued 8.90 million shares and warrants for 2.67 million shares. Total assets were $42.78 million, total liabilities $4.61 million, and stockholders’ equity $38.17 million at December 31, 2014. No notes payable remained outstanding at year-end; current liabilities were $2.34 million, and deferred taxes were $2.27 million.
Material changes and unusual items
- Working capital improved substantially following the private placement; the company said available cash was expected to fund planned operations at least through December 31, 2015 and into the first half of 2016, while warning that additional funds could be needed sooner.
- Research and development spending rose substantially as the company shifted toward drug development. Management expected R&D expense to increase further in 2015.
- A fourth-quarter strategic review narrowed development priorities to RES-529 for AMD and glioblastoma and RES-440 for acne. Abandonment of certain Canterbury/Hygeia cosmeceutical programs led to the $6.67 million impairment.
- The company corrected prior-period misstatements in the fourth quarter. Management said the corrections reduced fourth-quarter continuing loss by approximately $2.4 million and net loss by approximately $2.2 million, with no cash-flow impact; it concluded prior periods were not materially misstated.
- The company settled a property-damage claim for $150,000 against a previously accrued $393,592, recording a $243,592 gain. A separate lawsuit by former CEO Paul Feller sought unspecified damages; the company sought arbitration and said the outcome and potential loss could not be estimated.
- Gross contractual obligations were $6.40 million, including $4.52 million for employee contracts, $1.03 million for rent and $0.79 million in purchase obligations. The company disclosed no material off-balance-sheet arrangements.
Outlook, risks and governance
Management planned additional RES-529 AMD studies and Phase I/II studies for glioblastoma and RES-440 acne in 2016, subject to completing manufacturing, preclinical and other preparatory work. RES-529 received FDA orphan drug designation for glioblastoma in January 2015. These plans were forward-looking, not assured milestones.
Key risks include early-stage clinical and regulatory uncertainty, continued losses and need for additional financing, dependence on third-party manufacturers and clinical contractors, limited commercial infrastructure, competition, reimbursement and pricing pressure, and patent and licensing risks. The company had no commercial-scale manufacturing facilities, no formal commercial manufacturing agreements, and no sales or marketing personnel. It also warned that additional equity financing could dilute stockholders.
The financial statements received an unqualified audit opinion. Management concluded internal control over financial reporting was effective as of year-end, after remediation efforts addressing previously reported material weaknesses; the auditor did not provide an internal-control attestation. The company reported fourth-quarter corrections and had changed its auditor in November 2014.
Important facts for investors to verify
- Whether the cash balance and operating burn support management’s stated runway, and what additional financing may be required.
- Progress and funding for RES-529 and RES-440 development plans, including the stated 2016 trial targets and required CMC/preclinical work.
- The scope and accounting effects of the fourth-quarter corrections, and the basis for management’s conclusion that prior periods were not materially misstated.
- The outcome and potential financial exposure of the former CEO lawsuit and any other contingencies.
- Potential dilution from outstanding warrants and options; the company reported 4.82 million warrants and 3.65 million options outstanding at year-end.
- Whether internal-control remediation is sustained, given prior weaknesses and the absence of an auditor attestation.